Remed Co

Remed Co Capital Intensity

The Capital Intensity Ratio of Remed Co (302550.KQ) as of Nov 19, 2026 is 219.99 %. In the previous year, Capital Intensity Ratio was 231.13 % — a change of -4.82% (lower).

Capital Intensity

219.99 %

YoY

-4.82%

Last updated:

Capital Intensity Ratio of Remed Co is 2025 219.99 % . Capital Intensity Ratio of Remed Co was 2024 231.13 % . It decreases by -4.82% lower compared to the previous year.

The Remed Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
268.77 KRW
Jan 1, 2019
188.38 KRW
Jan 1, 2020
441.68 KRW
Jan 1, 2021
382.26 KRW
Jan 1, 2022
365.70 KRW
Jan 1, 2023
297.04 KRW
Jan 1, 2024
231.13 KRW
Jan 1, 2025
219.99 KRW
The Remed Co Capital Intensity history
YEARCapital IntensityYoY
219.99 %-4.82%
231.13 %-22.19%
297.04 %-18.77%
365.70 %-4.33%
382.26 %-13.45%
441.68 %+134.46%
188.38 %-29.91%
268.77 %+33.20%
201.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Capital Intensity Ratio of Remed Co is 219.99 % in 2025.

Capital Intensity Ratio of Remed Co changed from 231.13 % to 219.99 %, representing a -4.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Remed Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Remed Co

All Key Metrics — Remed Co